Table 1. Patient demographics, by nodal status and Recurrence Score assay status (N=241,681).
| Category | Parameter |
Node-negative, HR+ (N=184,190) |
Node-positive (N+(mic,1-3))a, HR+ (N=57,491) |
||
|---|---|---|---|---|---|
| HER2− With RS (N=40,134) | HER2±b Without RS (N=144,056) | HER2− With RS (N=4,691) | HER2±b Without RS (N=52,800) | ||
| n (%) | n (%) | n (%) | n (%) | ||
| Age | <40 years | 1,480 (3.7) | 4,827 (3.4) | 165 (3.5) | 3,889 (7.4) |
| 40–49 years | 9,350 (23.3) | 21,492 (14.9) | 853 (18.2) | 12,513 (23.7) | |
| 50–59 years | 12,744 (31.8) | 31,230 (21.7) | 1,375 (29.3) | 14,032 (26.6) | |
| 60–69 years | 11,913 (29.7) | 35,676 (24.8) | 1,418 (30.2) | 11,536 (21.8) | |
| 70–79 years | 4,173 (10.4) | 30,548 (21.2) | 778 (16.6) | 6,952 (13.2) | |
| ⩾80 years | 474 (1.2) | 20,283 (14.1) | 102 (2.2) | 3,878 (7.3) | |
| Sex | Male | 235 (0.6) | 999 (0.7) | 34 (0.7) | 559 (1.1) |
| Female | 39,899 (99.4) | 143,057 (99.3) | 4,657 (99.3) | 52,241 (98.9) | |
| Race | White | 33,684 (83.9) | 119,790 (83.2) | 4,021 (85.7) | 42,723 (80.9) |
| Black | 2,890 (7.2) | 11,539 (8.0) | 328 (7.0) | 5,357 (10.1) | |
| Other | 3,321 (8.3) | 11,940 (8.3) | 320 (6.8) | 4,434 (8.4) | |
| Unknown | 239 (0.6) | 787 (0.5) | 22 (0.5) | 286 (0.5) | |
| Tumor sizec | ⩽5 mm | 1,281 (3.2) | 20,601 (14.6) | 142 (3.0) | 1,393 (2.7) |
| >5–10 mm | 8,724 (21.9) | 36,005 (25.5) | 689 (14.8) | 4,339 (8.4) | |
| >10–20 mm | 21,100 (52.9) | 51,530 (36.5) | 2,332 (50.0) | 19,036 (36.7) | |
| >20–40 mm | 7,847 (19.7) | 26,521 (18.8) | 1,271 (27.2) | 20,078 (38.7) | |
| >40 mm | 914 (2.3) | 6,465 (4.6) | 233 (5.0) | 7,030 (13.6) | |
| Tumor gradec | Well | 11,208 (28.8) | 44,742 (32.9) | 1,333 (29.0) | 8,525 (16.8) |
| Moderate | 21,035 (54.0) | 62,320 (45.8) | 2,517 (54.8) | 25,334 (50.1) | |
| Poord | 6,704 (17.2) | 28,888 (21.2) | 742 (16.2) | 16,742 (33.1) | |
| Reported CT use | No/unknown | 31,023 (77.3) | 112,008 (77.8) | 3,048 (65.0) | 17,258 (32.7) |
| Yes | 9,111 (22.7) | 32,048 (22.2) | 1,643 (35.0) | 35,542 (67.3) | |
Abbreviations: CT, chemotherapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; RS, Recurrence Score result.
a
Excludes patients with ⩾4 positive nodes or unknown/missing nodal status.
b
Excludes patients with HER2-positive breast cancer in cohorts with Recurrence Score results, based on 21-gene assay quantitative single-gene HER2 result (by reverse transcription-PCR); includes patients with HER2-positive breast cancer in cohorts without Recurrence Score results because HER2 status was not reported to SEER before 2010.
c
Among patients in the cohort with nonmissing information.
d
Includes undifferentiated and anaplastic tumors.